Liang Han

机构：Jiangsu University, Xuzhou Medical College, Xuzhou Cancer Hospital, Xuzhou Central Hospital, Maternal and Child Health Hospital of Xuzhou · ORCID：0000-0003-3578-2914

发表论文 82 篇 · 总被引 3285 次 · h-index 28

代表论文

• NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer (2025 · Molecular Cancer · 被引 51)
• ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor. (2023 · Journal of Clinical Oncology · 被引 27)
• ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). (2024 · Journal of Clinical Oncology · 被引 24)
• Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer (2024 · Cancer Cell · 被引 22)
• Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. (2024 · Journal of Clinical Oncology · 被引 14)
• 8q24 derived ZNF252P promotes tumorigenesis by driving phase separation to activate c-Myc mediated feedback loop (2025 · Nature Communications · 被引 9)